Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice

Gynecologic Oncology

Volumn 109, Issue 3, 2008, Pages 388-393

  Santillan, Antonio ^a   Govan, Linda ^a   Zahurak, Marianna L ^a   Diaz Montes, Teresa P ^a   Giuntoli II, Robert L ^a   Bristow, Robert E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Healthcare costs; Pap test; Surveillance

Indexed keywords

ARTICLE; CANCER SCREENING; CLINICAL PATHWAY; COST BENEFIT ANALYSIS; COST CONTROL; ENDOMETRIUM CANCER; FEASIBILITY STUDY; FEMALE; GYNECOLOGIC CANCER; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; OUTPATIENT CARE; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; STATISTICAL ANALYSIS; STUDENT T TEST; UNITED STATES; UTERINE CERVIX CANCER; VAGINA CANCER;

CRITICAL PATHWAYS; FEASIBILITY STUDIES; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGY; HEALTH CARE COSTS; HUMANS; MASS SCREENING; MEDICAL ONCOLOGY; VAGINAL SMEARS;

EID: 44549085533     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.01.006     Document Type: Article

References (22)

1. Barnhill D., O'Connor D., Farley J., Teneriello M., Armstrong D., and Park R. Clinical surveillance of gynecologic cancer patients. Gynecol Oncol 46 (1992) 275-280
2. Tjalma W.A.A., van Dam P.A., Makar A.P., and Cruickshanks D.J. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer 14 (2004) 931-937
3. Bristow R.E., Purinton S., Santillan A., Diaz-Montes T., Gardner G.J., and Giuntoli II R.L. Cost effectiveness of routine vaginal cytology for endometrial cancer surveillances. Gynecol Oncol 103 2 (2006) 709-713
4. Hospital Cost Report CMS-2552-96, Centers for Medicare & Medicaid Services, U.S. Department of Health & Human Services; 2006. http://www.cms.hhs.gov/CostReports/02_HospitalCostReport.asp.
5. American Cancer Society. Cancer Facts and Figures. 2007 (2007), American Cancer Society, Atlanta. http://www.cancer.org/docroot/STT/stt_0.asp Available from: http://www.cancer.org/docroot/STT/stt_0.asp
6. Field M.J., and Lohr K.N. Clinical Practice Guidelines (1990), Institute of Medicine, Washington DC
7. American College of Obstetrics and Gynecology. Cervical Cytology: Evaluation and Management of Abnormalities. Washington, DC: Technical Bulletin No 183, August 1993.
8. Gadducci A., Cosio S., Fanucchi A., Cristofani R., and Genazzani A.R. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 20 (2000) 1977-1984
9. Shumsky A.G., Stuart G.C.E., Brasher P.M., Nation J.G., Robertson D.I., and Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 55 (1994) 229-233
10. Salvesen H.B., Akslen L.A., Iversen T., and Iversen O.E. Recurrence of endometrial carcinoma and the value of routine follow-up. Br J Obstet Gynaecol 104 (1997) 1302-1307
11. Berchuck A., Anspach C., Evans A.C., Soper J.T., Rodriguez G.C., Dodge R., et al. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 59 (1995) 20-24
12. Reddoch J.M., Burke T.W., Morris M., Tornos C., Levenback C., and Gershenson D.M. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 59 (1995) 221-225
13. Cooper A.L., Dornfeld-Finke J.M., Banks H.W., Davey D.D., and Modesitt S.C. Is cytologic screening and effective method of surveillance to detect vaginal recurrence of uterine cancer?. Obstet Gynecol 107 (2006) 71-76
14. Casey A.C., Park M., Holschneider C., Bozuk M., Punyasavatsut M., and Montz F.J. Apical vaginal recurrence of ovarian carcinoma: presentation, treatment and survival. Int J Gynecol Cancer 6 3 (1996) 200-204
15. Milam M.R., Sood A.K., King S., Bassett Jr. R.L., Lu K.H., Slomovitz B.M., Coleman R.L., and Ramirez P.T. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol 109 3 (Mar 2007) 641-646
16. Patsner B., Papanicolaou Smears Are of Little Value in the Post-Treatment Surveillance of Patients with Ovarian Epithelial Cancer. J Low Genit Tract Dis 5 (3), 130-132.
17. Soisson A.P., Geszler G., Soper J.T., et al. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy. Obstet Gynecol 76 (1990) 106-109
18. Larson M.L., Copeland L.J., Stringer C.A., et al. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 30 (1988) 381-387
19. Bodurka-Bevers D., Morris M., Eifel P.J., et al. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 78 (2000) 187-193
20. Morice P., Deyrolle C., Rey A., Atallah D., et al. Value of routine follow-up procedures for patients with stage I/II cervical cancer treated with combined surgery-radiation therapy. Ann Oncol 15 2 (Feb 2004) 218-223
21. Helms L.J., and Melnikow J. Determining costs of health care services for cost-effectiveness analyses. Med Care 37 (1999) 652-661
22. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M. Cancer statistics 2007. CA Cancer J Clin 57 (2007) 43-66